Cargando…

Mesothelioma

Detalles Bibliográficos
Autor principal:	Deraco, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267695/ https://www.ncbi.nlm.nih.gov/pubmed/34201425 http://dx.doi.org/10.3390/cancers13133127

Ejemplares similares

Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma
por: Kusamura, Shigeki, et al.
Publicado: (2023)

Malignant Mesothelioma
por: Pouliquen, Daniel L., et al.
Publicado: (2021)

Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma
por: Zaffaroni, Nadia, et al.
Publicado: (2007)

Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
por: Belfiore, Antonino, et al.
Publicado: (2019)

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts
por: De Cesare, Michelandrea, et al.
Publicado: (2016)

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism
por: El Bezawy, Rihan, et al.
Publicado: (2017)

Asbestos, mesothelioma and the legacy of shipbuilding in Belfast
por: Morrison, Patrick J
Publicado: (2008)

Malignant Pleural Mesothelioma: Time Is Running Out
por: Lococo, Filippo
Publicado: (2021)

Surgical series in mesothelioma: navigating between biases
por: Raskin, Jo, et al.
Publicado: (2023)

Malignant mesothelioma: health care awareness and preparedness
por: Capitani, Eduardo Mello De, et al.
Publicado: (2022)

Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2023)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

Malignant Pleural Mesothelioma—Does Ki67 Make the Grade?
por: Prall, Owen W.J.
Publicado: (2021)

Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions
por: Felley-Bosco, Emanuela
Publicado: (2018)

This special volume of mesothelioma is dedicated to my friend Adi Gazdar
por: Carbone, Michele
Publicado: (2020)

Mesothelioma: Hippo pathway as a target, lessons from COMMAND
por: Fennell, Dean A., et al.
Publicado: (2019)

Spare the lung: surgical treatment approach for malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2023)

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types
por: Tazzari, Marcella, et al.
Publicado: (2018)

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
por: Sciarrillo, Rocco, et al.
Publicado: (2018)

Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment
por: Ban, Cheng-Jun, et al.
Publicado: (2017)

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework
por: Bozzi, Fabio, et al.
Publicado: (2016)

The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma
por: Wheatley-Price, Paul, et al.
Publicado: (2022)

Commment on the review entitled “A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer” by Chiva LM and Gonzalez-Martin A.
por: Deraco, Marcello, et al.
Publicado: (2015)

Malignant Pleural Mesothelioma in Patients Who Previously Received Radiotherapy for Their First Malignant Tumor
por: Sekine, Ikuo, et al.
Publicado: (2020)

Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma
por: Migliore, Marcello, et al.
Publicado: (2021)

Managing Malignant Pleural Mesothelioma in the Age of Personalized Medicine: Where Are We and What Is Still Missing?
por: Stella, Giulia Maria, et al.
Publicado: (2022)

Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma
por: Branch, Kevin, et al.
Publicado: (2023)

FKBP5, a Modulator of Stress Responses Involved in Malignant Mesothelioma: The Link between Stress and Cancer †
por: Cugliari, Giovanni
Publicado: (2023)

miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma
por: El Bezawy, Rihan, et al.
Publicado: (2022)

Do we still need to debate the merits of pleurectomy/decortication vs. extrapleural pneumonectomy for malignant pleural mesothelioma?
por: Nakamura, Akifumi, et al.
Publicado: (2023)

Mesothelioma
por: Rao, Nagarjun, et al.
Publicado: (2022)

Rethought histologic classification of pleural mesothelioma to better treat: go forward from looking back
por: Astoul, Philippe
Publicado: (2020)

Peritoneal mesothelioma.
por: Kealey, W. D., et al.
Publicado: (1993)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Peritoneal mesothelioma.
por: Churg, J
Publicado: (1974)

Malignant mesothelioma
por: Moore, Alastair J, et al.
Publicado: (2008)

Malignant mesothelioma
por: Ahmed, Ishtiaq, et al.
Publicado: (2013)

Peritoneal mesothelioma
por: Greenbaum, Alissa, et al.
Publicado: (2020)

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
por: Li Petri, Giovanna, et al.
Publicado: (2020)

New Immunohistochemical Markers for Pleural Mesothelioma Subtyping
por: Di Stefano, Iosè, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_th9e2u2f6rbs4j15umfova81gi